Published On : October 2026
Demand for a surgical microcatheter is created one procedure at a time, so the way a hospital or surgery centre counts its glaucoma caseload largely determines how many devices it will buy.
The wider structure of the glaucoma surgical microcatheter market rests on two dimensions that this page brings together, which are procedure type and glaucoma type, and the pairing explains why two hospitals of similar size can have very different device requirements.
Procedure type in the report has four categories: canaloplasty, ab-interno canaloplasty, combined cataract and canaloplasty procedures and hybrid MIGS procedures.
Glaucoma type has four categories as well, namely primary open-angle glaucoma, normal-tension glaucoma, secondary open-angle glaucoma and pseudoexfoliative glaucoma.
The relationship between the two is a matter of eligibility and surgeon judgement, because the glaucoma type seen in a clinic influences which procedure categories a surgeon considers, and the procedure category in turn determines whether a microcatheter is needed at all.
This page treats those relationships as a demand-side map for suppliers and purchasing teams, and it does not make clinical recommendations or claim that any procedure suits any patient group.
For a purchasing manager, the useful point is that the glaucoma case mix of a facility is a forecasting input, since a clinic with a high share of one glaucoma type will repeatedly order the devices linked to the procedures usually chosen for it.
For a manufacturer, the same case mix tells it which of its product lines will be relevant to a given customer, and it explains why sales conversations in this category begin with questions about the patients a surgeon sees rather than about device features.
Case mix also changes over time as referral patterns, screening programmes and the availability of new devices alter the patients who reach surgery, so demand forecasts for a single facility need regular review.
|
BUYER INSIGHT A facility's glaucoma case mix is the most reliable predictor of which procedure categories it will perform, so suppliers who ask about case mix early in a conversation are usually better placed to size a realistic order. |
The first two procedure type categories are the base of the segment, and they differ mainly in the way the eye is entered rather than in the purpose of the device.
Canaloplasty is the established procedure category in which a microcatheter is passed through a channel in the eye as part of a glaucoma operation, and it is carried out in specialist glaucoma practice by surgeons trained in the technique.
Ab-interno canaloplasty uses a different route of entry, from inside the eye through a small corneal incision, and it has broadened the number of surgeons willing to perform the procedure because it follows a workflow familiar from cataract surgery.
This page deliberately describes these procedures only at the level needed to understand device demand, and it does not set out surgical steps or compare their results.
For device purchasing, the two categories create different buying patterns, since standalone canaloplasty is scheduled as a dedicated glaucoma operation with a predictable device requirement, while ab-interno canaloplasty is often added to an existing list and its device requirement follows the surgeon's decision on the day.
That difference affects inventory, because a surgery centre supporting ab-interno work may need to hold a modest stock of devices for cases that cannot be planned far ahead, whereas dedicated canaloplasty can be supplied closer to a fixed schedule.
Training expectations also differ, with established glaucoma surgeons needing limited support for a related device and cataract surgeons adopting the ab-interno route needing more structured training and proctoring.
Both categories draw on the same underlying family of microcatheter product types, so a supplier offering a range of devices can serve both, but the customer relationship, the training offer and the ordering pattern are different enough that many manufacturers manage them as separate commercial efforts.
Combined cataract and canaloplasty procedures are the largest procedure type category in the report, and they are the main reason glaucoma device demand is increasingly tied to cataract surgery volumes.
Cataract surgery is among the most commonly performed operations in ophthalmology, and a patient who has both a cataract and glaucoma can in some cases be offered a glaucoma procedure during the same visit to the operating theatre.
The commercial result is that the pool of eligible cases for a microcatheter is far larger than the pool of dedicated glaucoma operations, because every cataract list becomes a potential source of demand.
For manufacturers this changes the target customer, since the surgeon deciding whether to add a glaucoma step may be a cataract surgeon rather than a glaucoma specialist, and the training and evidence needed to persuade each group differ.
For purchasing teams, combined procedures change the budget picture, because device spending is tied to cataract volumes and to the way the facility is reimbursed for combined operations, rather than to a separate glaucoma budget.
Reimbursement is central here, since a combined procedure only becomes routine where the payer environment supports the added glaucoma step, and that is one reason adoption is faster in some countries than in others.
Scheduling matters too, because cataract lists are built around short operating slots, and a device that fits into that time without disrupting the list is easier for a surgery centre to adopt.
These factors make combined procedures a competitive battleground in the category, and manufacturers pay close attention to how each product fits cataract workflows when they design training and supply arrangements for the customers concerned.
|
MARKET SHIFT As combined cataract and glaucoma procedures become more routine, device demand follows cataract volumes rather than glaucoma clinic volumes, which widens the customer base and brings cataract surgeons into a purchasing decision once led by glaucoma specialists. |
Hybrid MIGS procedures are the fastest-growing procedure type category in the report, and they combine a microcatheter-based step with another minimally invasive glaucoma technique within a single operation.
Their importance for the market is that they enlarge the role of the microcatheter, which becomes one component of a combined approach rather than the sole device used in a procedure.
Buyers planning a hybrid programme need to look closely at microcatheter product types and platforms, since the compatibility of a microcatheter with the other devices in the operation affects what a facility must stock and which suppliers it must contract with.
Hybrid procedures also complicate purchasing, because the devices used may come from more than one manufacturer, and a facility may need to coordinate several supply agreements around a single operation.
Some suppliers respond by offering bundled arrangements, in which several devices are provided under one contract, and this is one route by which integrated surgical package procurement has gained ground in the report's procurement segmentation.
Clinical evidence is harder to assemble for hybrid procedures than for single-device procedures, since combinations vary between surgeons, and buyers therefore tend to rely more on surgeon experience and on peer practice than on formal published comparisons.
Reimbursement can also be less clear for hybrid procedures, because coding systems are built around single procedures, and facilities sometimes need to confirm with payers how a combined operation will be classified before committing to a programme.
Adoption therefore tends to begin in academic ophthalmology centres and specialist eye hospitals, where surgeons are comfortable with combinations, and to reach community surgery centres later, as reimbursement and training mature.
The first two glaucoma type categories account for the largest share of the glaucoma caseload in the segmentation, and they therefore anchor demand for most procedure categories.
Primary open-angle glaucoma is the most commonly encountered form in many markets and is the largest glaucoma type category in the report, which means procedure volumes for this group set the baseline for device demand.
Normal-tension glaucoma is a related category in which the condition progresses without the elevated measurements usually associated with the disease, and it is tracked separately because it presents differently in clinic and attracts specific attention from surgeons and referral networks.
This page does not discuss how any procedure performs for either group, since the report concerns market structure and makes no clinical claims.
From a commercial viewpoint, the volume in these two categories is spread across many surgeons and many facilities, which makes it a broad but fragmented source of demand rather than a concentrated one.
Suppliers serving this demand therefore rely on wide distribution, on training that reaches many surgeons and on reimbursement that makes adoption routine, because no single institution accounts for a large part of the volume.
Referral patterns matter as well, since many patients with these conditions are first identified by community eye care professionals, and the surgeons who eventually perform a procedure depend on those referral relationships for their case flow.
A facility's mix between these two glaucoma types is a useful planning input for buyers, because it feeds directly into forecasts of the procedure categories most likely to be performed and the devices to be stocked.
Secondary open-angle and pseudoexfoliative glaucoma form the second pair of glaucoma type categories, and they are smaller in volume but important for specialist centres.
Secondary open-angle glaucoma arises from an identifiable underlying cause rather than appearing without one, while pseudoexfoliative glaucoma is associated with a particular deposit pattern within the eye and is more common in some regions and age groups than others.
These categories matter commercially because their patients are more likely to be concentrated in specialist and academic centres, which affects where a supplier needs to focus its clinical and training effort.
Regional variation is a further factor, because the frequency of pseudoexfoliative glaucoma differs between countries, and manufacturers with a presence in the affected markets may see a higher proportion of procedure demand from this group.
The site of care for these patients, covered in end users and reimbursement environments, often decides how quickly a new device reaches them, since specialist centres tend to adopt earlier than community surgery centres.
A hospital treating a large proportion of these cases usually has the surgical expertise to evaluate newer devices and often takes part in clinical studies, which makes it an influential early adopter.
That influence extends beyond the hospital itself, because surgeons at specialist centres often train others and present at conferences, so their preferences shape what community surgeons later ask their own purchasing departments to buy.
For suppliers, winning a specialist centre in these categories can therefore have effects well beyond the volume that centre purchases directly, and many treat such centres as reference sites for their wider commercial effort.
The report tracks four procedure types (canaloplasty, ab-interno canaloplasty, combined cataract and canaloplasty procedures and hybrid MIGS procedures) across four glaucoma types (primary open-angle, normal-tension, secondary open-angle and pseudoexfoliative glaucoma).
Combined cataract and canaloplasty procedures are the largest category, because every cataract operating list becomes a potential source of demand, while hybrid MIGS procedures are the fastest-growing category.
A facility's glaucoma case mix indicates which procedure categories its surgeons will perform, and that determines the devices it needs to stock, so suppliers and buyers use case mix to forecast demand.
Devices used in a hybrid procedure may come from more than one manufacturer, so a facility may have to coordinate several supply agreements, and some suppliers respond with bundled arrangements covering several devices.
No. It describes market structure and demand patterns only and makes no clinical claims about efficacy, pressure reduction, complications or outcomes for any procedure, device or company.